• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants
AbstractDirect oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current evidence regarding DOAC use in diabetic patients included in the majority of recently conducted studies. Overall, in trials involving patients with atrial fibrillation, data seem to confirm at least a similar efficacy and ...
Source: Acta Diabetologica - September 23, 2019 Category: Endocrinology Source Type: research

Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus
ConclusionsThis study indicates a significantly more intense DE‐induced anticoagulation in diabetic rats that does not seem to be solely related to altered kidney function, and demonstrates that plasma cholesterol can significantly affect DE‐anticoagulation in this setting. These results could explain the similar benefits of DE on stroke prevention in patients with and without DM, despite the significantly higher intrinsic thrombotic risk of the former, as well as the lack of benefit of reducing major bleeding in diabetics.
Source: Journal of Diabetes - July 1, 2017 Category: Endocrinology Authors: Alina Scridon, Marcel Perian, Alina M ărginean, Adina Huțanu, Doina Gherțescu, Adriana Vântu, Paul Ciprian Fișcă, Philippe Chevalier, Răzvan Constantin Șerban, Dan Dobreanu Tags: Original Article Source Type: research

Ultrasound Guided Fine Needle Aspiration Biopsy of Thyroid Nodules in Patients taking Novel Oral Anticoagulants.
Conclusions: It has previously been established that patients on historical anticoagulant agents do not need to discontinue therapy prior to minor procedures such as needle aspirations or dental procedures. Therefore, in patients currently taking dabigatran, rivaroxaban, or apixaban, we conclude that is reasonable and safe to continue the novel oral anticoagulant agents prior to USGFNAB of thyroid nodules without major risk of bleeding. This conclusion is based not only on the fact that minor procedures are considered safe in patients on NOACs, but also because patients on historical anticoagulant agents do not need to dis...
Source: Thyroid : official journal of the American Thyroid Association - January 16, 2015 Category: Endocrinology Tags: Thyroid Source Type: research